Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors.

[1]  J. Holst.  Glucagon-like peptide-1: physiology and therapeutic potential , 2005 .

[2]  R. Mentlein.  Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs , 2005, Expert opinion on investigational drugs.

[3]  J. Holst,et al.  Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. , 2004, Current opinion in pharmacology.

[4]  J. Holst,et al.  Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? , 2004, Expert opinion on investigational drugs.

[5]  C. Deacon.  Therapeutic strategies based on glucagon-like peptide 1. , 2004, Diabetes.

[6]  Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. , 2004, Journal of medicinal chemistry.

[7]  L. B. Knudsen.  Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. , 2004, Journal of medicinal chemistry.

[8]  Bo Ahrén,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2078–2084 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031907 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels , 2022 .

[9]  Ping Chen,et al.  Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[10]  D. D’Alessio,et al.  Gut peptides in the treatment of diabetes mellitus , 2004, Expert opinion on investigational drugs.

[11]  A. Lambeir,et al.  Design, synthesis, and SAR of potent and selective dipeptide-derived inhibitors for dipeptidyl peptidases. , 2003, Journal of medicinal chemistry.

[12]  W. Banks,et al.  Glucagon-like peptide-1 receptor is involved in learning and neuroprotection , 2003, Nature Medicine.

[13]  R. Young,et al.  Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity. , 2003, Journal of medicinal chemistry.

[14]  Robert Pearlstein,et al.  Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. , 2003, Journal of medicinal chemistry.

[15]  C. Craik,et al.  Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. , 2003, The Biochemical journal.

[16]  U. Kazmaier.  Application of the Chelate‐Enolate Claisen Rearrangement to The Synthesis of γ,δ‐Unsaturated Amino Acids , 1997 .

[17]  E. Corey,et al.  Novel electronic effects of remote substituents on the oxazaborolidine-catalyzed enantioselective reduction of ketones , 1995 .

[18]  U. Kazmaier.  Synthesis of Unsaturated Amino Acids by [3,3]‐Sigmatropic Rearrangement of Chelate‐Bridged Glycine Ester Enolates , 1994 .

[19]  E. Corey,et al.  A new system for catalytic enantioselective reduction of achiral ketones to chiral alcohols. Synthesis of chiral α-hydroxy acids , 1990 .